Denufosol tetrasodium

CAS : 318250-11-2

Ref. 3D-ND45968

Informations sur le produit

• Nom: Denufosol tetrasodium
• Synonymes: 2'-Deoxycytidine P'''-5'-ester with uridine 5'-(pentahydrogen tetraphosphate) sodium saltUridine 5'-(pentahydrogen tetraphosphate), P'5'-ester 2'-deoxycytidineINS 37217[[(3S,5R)-5-(4-Amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyp, dCp4U, Ins-37217, Uridine 5'-(pentahydrogen tetraphosphate) P'''--5'-ester with 2'-deoxycytidine tetrasodium salt, tetrasodium [[[[(3S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl hydrogen phosphate, tetrasodium [[[[(2R,3S,5R)-5-(4-amino-2-oxo-pyrimidin-1-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-oxido-phosphoryl]oxy-oxido-phosphoryl]oxy-oxido-phosphoryl] [(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl phosphate

Description

A P2Y2 receptor agonist that has been studied in cystic fibrosis and retinal diseases such as retinal detachment. Denufosol was studied as an inhaled drug for cystic fibrosis, due to its ability to activate an alternative chloride channel and avoiding the defective CFTR chloride channel. This enhances hydration of the lung mucosa and improves mucociliary clearance. The drug did not progress from phase III clinical trials. Denufosol resulted in subretinal fluid reabsorption in in vivo model of retinal detachment.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 861.25 g/mol
• Formule: C₁₈H₂₃N₅Na₄O₂₁P₄
• Degré de pureté: Min. 90 Area-%
• Couleur/Forme: Powder